P-96 Quality of life in late-stage cancer patients on immune checkpoint inhibitor therapy

Immune checkpoint inhibitors are a successful therapy for cancer patients and patient related outcomes compared with cytotoxics. Unfortunately (ICI) can have unpredictable toxicities that severe impact on Health-related Quality of life may lead to treatment withdrawal. This study attempts further characterise patient’s quality these treatments identify any trends in groups. 17 late-stage who receiving ICI Bons Secours Hospital were recruited. Completed Functional Assessment Cancer Therapy- Checkpoint Modulator (FACT-ICM) questionnaires collected scored. Patient electronic records reviewed all other outcome measures. A higher score indicates life. Patients receive from 0 208. Outcome measures: Life score, Side effects graded by NCI-CTCAE, best clinical response CT scan using RECIST criteria, Age, Gender, Current treatment, ECOG status, comorbidities, type grade. Time since first last immune inhibitor (if withdrew treatment). FACT-ICM scores had Mean 168.88 ± 18.398. grouped according their factors see if this affected scores. concurrent chemotherapy mean 157.7 whilst not 175.0. At sample size no statistically significant observed between factors. Whilst therapy, lower appears be linked poor response, presence autoimmune high age chemotherapy. affect the ICI. Further research more recruited is needed greater statistical power understand relationships cancer. Chemotherapy should only used when unavoidable brief period combination.